Lilly touts Cyramza lung cancer data, as AZ’s Tagrisso grows even more powerful

Full data supporting Eli Lilly’s Cyramza in previously untreated EGFR lung cancer patients are out. But an approval would mean going up against AstraZeneca's new king, Tagrisso—and it's become an even more formidable force with a growing arsenal of clinical evidence.